Fusion Pharmaceuticals Inc (NAS:FUSN)
$ 21.55 0 (0%) Market Cap: 1.83 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 7.56 GF Score: 38/100

Fusion Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 04:55PM GMT
Release Date Price: $3.56 (+21.09%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael Ulz, one of the biotech analysts here. And it's my pleasure to introduce the team from Fusion Pharmaceuticals, starting with John Crowley, CFO; as well as Eric Burak, Chief Technology Officer.

But before we get started today, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please feel free to reach out to your Morgan Stanley sales rep. With that we can jump right in the Q&A.

Questions & Answers

Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

John and Eric, thanks for joining us today. And maybe for people who aren't familiar with Fusion and more broadly, radiopharmaceuticals, if you can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot